Sofinnova Partners, a life sciences venture capital firm based in Paris, London, and Milan, has launched Sofinnova.AI, an artificial intelligence platform that integrates advanced computational capabilities with the firm’s industry expertise.
This will create one of the world’s largest, longitudinal, annotated, proprietary data sets on early-stage life science companies, enabling insights into life sciences innovation discovery, and enhancing deal origination and portfolio growth.
Sofinnova.AI is based on a structured, continuously updated database that tracks the global corpus of human scientific knowledge in real-time. The database contains:
- > 90 million scientific publication authors
- > 40 million scientific publications
- > 100,000 research institutes
- > 4.5 million published patents
- > 450,000 clinical trials
- > 2 million companies and 1.5 million founders
In addition to the structured database, Sofinnova.AI includes all the proprietary information and expert opinions accumulated by the firm over time. A suite of proprietary data-analysis tools, including a bespoke large language model (LLM), technology akin to ChatGPT, allows the Sofinnova teams to query this massive database in the most efficient way. These tools will enable the firm to pinpoint hidden hubs of life science research, predict emerging scientific trends, and connect with the next generation of innovators, among many other use cases.
Commenting on the launch, Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: “Sofinnova.AI super-charges the conventional, artisanal approach of sourcing and building investment opportunities — a process that has, until now, been solely reliant on our personal networks and the meticulous task of connecting disparate information over months if not years. By harnessing billions of data points spanning scientific literature, emerging therapeutic fields, and technological breakthroughs, and amalgamating this with all the proprietary knowledge accumulated over Sofinnova’s 50 years of expertise, Sofinnova.AI will enable us to identify the next ‘moonshots’ with unprecedented speed and precision.“
Papiernik added: “Our dedicated team of data scientists and AI experts has spent the past four years meticulously crafting Sofinnova.AI. We believe it will enable us to evaluate opportunities from a much broader vantage point, allowing us to look beyond the horizon in the most efficient way, so we can spend more time focusing on people. Sofinnova.AI will enhance our investment strategies by enabling us to focus more time on leveraging our collective human intelligence to strengthen relationships with our entrepreneurs. It will enable us to stay at the vanguard of innovation in order to fund those truly shaping the future of life sciences.“
Founded in 1972, Sofinnova Partners is a venture capital firm in Europe, which has backed over 500 companies. Today, Sofinnova Partners has over €2.5 billion under management.